Axonics, Inc. (AXNX) Misses Q2 EPS by 10c, Revenues Beat; Raises Revenue Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. META
4. NFLX
5. TSLA
6. ISRG
7. SMCI
8. GOOGL
9. RTX
10. USO

Go back to Axonics, Inc. (AXNX) Misses Q2 EPS by 10c, Revenues Beat; Raises Revenue Guidance

Axonics® Reports Second Quarter 2021 Financial Results

August 5, 2021 4:01 PM EDT

Total revenue of $45.9 million in 2Q21, including record SNM revenue of $40.2 million

Bulkamid® revenue of $5.7 million in first full quarter since acquisition

Fiscal year 2021 revenue guidance increased to a range of $186 million to $188 million

IRVINE, Calif.--(BUSINESS WIRE)-- Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the second quarter ended June 30, 2021.

This quarters record revenue result reflects the growing... More